Represented Mylan in three Hatch-Waxman litigations in the District of New Jersey and the Federal Circuit Court of Appeals over patent rights to naproxen/esomeprazole magnesium tablets (Vimovo®), used to treat the risk of ulcer formation in patients requiring long-term treatment with non-steroidal anti-inflammatory drugs. After Mylan successfully obtained judgments of invalidity of four patents, a settlement agreement was reached.